XSHE
300030
Market cap272mUSD
Jul 10, Last price
6.17CNY
1D
3.18%
1Q
-19.97%
Jan 2017
-54.83%
IPO
66.36%
Name
GZ IMPROVE MEDICAL INSTRUMENTS CO.
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Improve Medical Instruments Co., Ltd. operates as an international supplier, delivering advanced technologies, medical products, and critical services to clinical laboratories and for patient care, spanning both the Chinese market and global regions. A significant portion of its product portfolio comprises leading brands such as IMPROVACUTER evacuated blood collection systems, IMPROMINI capillary blood collection systems, IMPROSWAB microbiological transport systems, IMPRONURSE infusion and syringe pumps, and LONGX urine analysis platforms, alongside an assortment of in-vitro diagnostic reagents. Furthermore, the company's comprehensive offerings extend to a wide range of ancillary equipment and disposables, including blood collection needles, pulsewave blood pressure monitors, thrombosis viscoelastic analysis systems, feces analysis systems, automated blood and urine collection tube preparation systems, graphical user interface (GUI) devices, intelligent sorting units, multi-functional blood collection workstations, smart queue management systems, automatic tube packing systems, and consumable labels. Originally incorporated in 1996 as Guangzhou Improve Medical Instruments Co., Ltd., the enterprise maintains its headquarters in Guangzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||